hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06385977, orgStudyIdInfo id: ShaanxiPPH, briefTitle: Risk Factors for Chronic Prostatitis Patients in Northwest China, statusModule overallStatus: RECRUITING, startDateStruct date: 2016-01, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Shaanxi Provincial People's Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the risk factors of lifestyle, medication and sexual habits in adult chronic prostatitis / chronic pelvic pain syndrome patients. The main questions it aims to answer are:* Is lifestyle, medication, and sexual habits related to chronic prostatitis / chronic pelvic pain syndrome* Is there any medication available to protect men from chronic prostatitis / chronic pelvic pain syndrome.Participants will:* Independently receive a survey questionnaire on lifestyle, medication, and sexual habits.* Symptomatic individuals will undergo additional prostate fluid examination for diagnosis.Researchers will compare healthy adult males to see if there are differences on lifestyle, medication and sexual habits between the two groups., conditionsModule conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: lifestyle, interventions name: sexual habits, interventions name: medication, outcomesModule primaryOutcomes measure: Odds Ratio, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shaanxi Provincial People's Hospital, status: RECRUITING, city: Xi'an, state: Shaanxi, zip: 710061, country: China, contacts name: Qian Deng, Doctor, role: CONTACT, phone: 86-029-85251331, phoneExt: 2079, email: dengqian@xiyi.edu.cn, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06385964, orgStudyIdInfo id: SHR-4597-101, briefTitle: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Guangdong Hengrui Pharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The primary objective of this randomized, double-blind, single/multiple ascending dose, placebo-controlled Phase I clinical trial was to evaluate the safety and tolerability of SHR-4597 in healthy subjects and asthmatic patients. The study consists of two parts: Part 1 involves single ascending inhalation dose in healthy subjects; Part 2 involves multiple ascending inhalation dose in asthmatic patients, further divided into Part 2A: multiple ascending inhalation dose in mild to moderate asthmatic patients, and Part 2B: multiple ascending inhalation dose in moderate to severe asthmatic patients. Subsequent lung pharmacokinetic studies of SHR-4597 inhalation will be conducted based on patients' PKPD data., conditionsModule conditions: Healthy Subjects, conditions: Asthmatic Patients, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: SHR-4597, interventions name: Placebo, outcomesModule primaryOutcomes measure: Incidence and severity of inhalant adverse events after 4 days of single inhalation of SHR4597 in healthy subjects, primaryOutcomes measure: Incidence and severity of inhalant adverse events after 16 days of multiple inhalation of SHR4597 in asthmatic patients,, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385938, orgStudyIdInfo id: 23-012048, briefTitle: Ultrasound Imaging and Quantitative Vibro-Acoustic Assessment of Rickets Under the Age of Ten, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The goal of this study is to find out if the use of ultrasound pictures of bones can spot changes in the growth areas of children with rickets, a condition that affects how bones harden. Researchers want to see if these ultrasound pictures can help tell the difference between children who have rickets and those who don't., conditionsModule conditions: Rickets, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound with quantitative vibro-acoustic assessment, outcomesModule primaryOutcomes measure: Relationship of quantitative vibro-acoustic ultrasound and rickets severity score, secondaryOutcomes measure: Relationship of ultrasound images with radiographic evidence of rickets, secondaryOutcomes measure: Case-control comparison of quantitative vibro-acoustic ultrasound measurements between children with rickets and control subjects, secondaryOutcomes measure: Longitudinal changes in vibro-acoustic ultrasound measurements with treatment of rickets, eligibilityModule sex: ALL, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Mayo Clinic Minnesota, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Mary A Johnson, role: CONTACT, phone: 507-422-6823, email: johnson.mary15@mayo.edu, contacts name: Tom D. Thacher, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06385925, orgStudyIdInfo id: TSN1611-2023-101, briefTitle: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-10-30, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Tyligand Bioscience (Shanghai) Limited, class: INDUSTRY, descriptionModule briefSummary: The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part., conditionsModule conditions: Malignant Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: TSN1611, outcomesModule primaryOutcomes measure: Dose limiting toxicities (DLTs) in phase 1 part, primaryOutcomes measure: Objective response rate (ORR) in phase 2 part, secondaryOutcomes measure: Adverse events, secondaryOutcomes measure: Area under the plasma concentration-time curve (AUC), secondaryOutcomes measure: Maximum blood concentrations (Cmax), secondaryOutcomes measure: Time to maximum blood concentration (Tmax), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Time to response (TTR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, status: NOT_YET_RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Siqing Fu, MD, PhD, role: CONTACT, geoPoint lat: 29.76328, lon: -95.36327, locations facility: NEXT Oncology, status: RECRUITING, city: San Antonio, state: Texas, zip: 78229, country: United States, contacts name: David Sommerhalder, MD, PhD, role: CONTACT, geoPoint lat: 29.42412, lon: -98.49363, locations facility: NEXT Virginia, status: RECRUITING, city: Fairfax, state: Virginia, zip: 22031, country: United States, contacts name: Alexander Spira, MD, PhD, role: CONTACT, geoPoint lat: 38.84622, lon: -77.30637, hasResults: False
protocolSection identificationModule nctId: NCT06385912, orgStudyIdInfo id: 2024-TJ-SLIDS, briefTitle: Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2006-07-01, primaryCompletionDateStruct date: 2021-02-10, completionDateStruct date: 2021-02-10, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Tongji Hospital, class: OTHER, descriptionModule briefSummary: The study aims to investigate the prognostic and postoperative complication relevance of lymphadenectomy in advanced epithelial ovarian cancer patients who received neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The main question it aims to answer is:Does systematic lymphadenectomy during interval debulking surgery have a significant impact on survival in patients with advanced epithelial ovarian cancer who have received neoadjuvant chemotherapy?The progression-free survival (PFS), overall survival (OS), and postoperative complication were compared between the lymphadenectomy and no lymphadenectomy groups to answer the question., conditionsModule conditions: Ovarian Cancer, conditions: Postoperative Complications, conditions: Neoadjuvant Therapy, conditions: Lymph Node Excision, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1090, type: ACTUAL, armsInterventionsModule interventions name: lymphadenectomy, outcomesModule primaryOutcomes measure: Progression free survival (PFS), primaryOutcomes measure: Overall survival (OS), eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430030, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06385899, orgStudyIdInfo id: : Poorly controlled T2DM-12, briefTitle: Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2023-01-01, completionDateStruct date: 2023-03-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Goztepe Prof Dr Suleyman Yalcın City Hospital, class: OTHER, descriptionModule briefSummary: In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%. The pandemic has also affected diabetic patients. It is aimed to determine the characteristics of patients with type 2 diabetes (HbA1c \>=10) with poor metabolic control and to evaluate the extent to which metabolic control can be achieved in 12 months., conditionsModule conditions: Type 2 Diabetes, conditions: Poor Glycemic Control, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 266, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Changes in HbA1c levels after 12 months treatment, primaryOutcomes measure: percentage of patients who reached the HbA1c target of equal to or below 7%, secondaryOutcomes measure: The effect of education on the HbA1c changes, secondaryOutcomes measure: The effect of depression on the HbA1c changes, secondaryOutcomes measure: The effect of the level of physical activity on the HbA1c changes, secondaryOutcomes measure: The effect of weight loss on the HbA1c changes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06385873, orgStudyIdInfo id: 2024-SR-233, briefTitle: RC48 Combined With Adebrelimab and Apatinib and S-1 of the Neoadjuvant Therapy of Locally Advanced Gastric Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-05-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression., conditionsModule conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: RC48, interventions name: Adebrelimab, interventions name: Apatinib, interventions name: S-1, outcomesModule primaryOutcomes measure: Pathological Complete Response Rate (pCR), secondaryOutcomes measure: Major Pathological Response rate (MPR), secondaryOutcomes measure: R0 Resection rate, secondaryOutcomes measure: Disease-Free Survival (DFS）, secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385860, orgStudyIdInfo id: GTMGS0423, briefTitle: Prediction Model for Early Biliary Stasis After Bariatric Surgery, acronym: PM-EBS-BS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: Developing and validating a predictive model to estimate the risk of early biliary stasis following bariatric surgery, conditionsModule conditions: Obesity, conditions: Diabetes, conditions: Gallstones, conditions: Biliary Stasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: early biliary stasis, primaryOutcomes measure: prediction model, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385847, orgStudyIdInfo id: GOMIMP, briefTitle: To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Xiamen University, class: OTHER, descriptionModule briefSummary: The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer, conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Prospective, randomized, open-label, cross-over phase II trial, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Zoladex, interventions name: LY01005, outcomesModule primaryOutcomes measure: Patient preference, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Xiamen University, status: RECRUITING, city: Xiamen, state: Fujian, zip: 361003, country: China, contacts name: Xuegang Wang, doctor, role: CONTACT, phone: 15960263909, email: stefwxg@163.com, geoPoint lat: 24.47979, lon: 118.08187, hasResults: False
protocolSection identificationModule nctId: NCT06385834, orgStudyIdInfo id: LY2014-041-A, briefTitle: The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2028-04-30, completionDateStruct date: 2028-07-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: The aim of the study was to intervene in the Aerobic exercise time of patients with STEMI and to explore the optimal exercise time for STEMI patients, conditionsModule conditions: ST-segment Elevation Myocardial Infarction (STEMI), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study was divided into three groups: morning intervention group (8:00-9:00AM), evening intervention group (16:00-17:00AM) and control group, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: In this study, outcome measurement personnel and intervention personnel were separated during the whole process of the experiment, outcome measurement personnel did not know the grouping status, intervention personnel and rehabilitation therapists did not participate in the outcome measurement work., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 201, type: ESTIMATED, armsInterventionsModule interventions name: Morning aerobic exercise, interventions name: Evening aerobic exercise, outcomesModule primaryOutcomes measure: left ventricle ejection fraction, secondaryOutcomes measure: Oxygen consumption, secondaryOutcomes measure: Endothelial Function, secondaryOutcomes measure: Skeletal muscle and fat mass, secondaryOutcomes measure: Cardiac structure, secondaryOutcomes measure: One year major Adverse Cardiovascular Events, secondaryOutcomes measure: VE/VCO2-SLOPE, secondaryOutcomes measure: Flow-mediated dilation, secondaryOutcomes measure: glucose, secondaryOutcomes measure: Blood lipid, secondaryOutcomes measure: N-terminal pro-BNP, eligibilityModule sex: ALL, minimumAge: 17 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385808, orgStudyIdInfo id: XJTU1AF-CRF-2023-XK014, briefTitle: Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital Xi'an Jiaotong University, class: OTHER, descriptionModule briefSummary: The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia. The secondary purpose of the study was to observe the safety of MTBF regimen in these patients., conditionsModule conditions: Relapse Leukemia, conditions: Refractory Acute Myeloid Leukemia, conditions: Conditioning, conditions: Hematopoietic Stem Cell Transplantation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The relapsed or refractory acute myeloid leukemia patients will pretreated with the MTBF regimen prior to salvageable allogeneic hematopoietic stem cells. The one-year recurrence-free survival after transplantation of these patients and the safty of the MTBF regimen will be studied., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ESTIMATED, armsInterventionsModule interventions name: MTBF regimen, outcomesModule primaryOutcomes measure: Recurrence rate, secondaryOutcomes measure: Incidence and Severity of non-hematological adverse events (NCI CTCAE v5.0), secondaryOutcomes measure: Neutrophil recovery time, secondaryOutcomes measure: Platelet recovery time, secondaryOutcomes measure: OS, secondaryOutcomes measure: PFS, otherOutcomes measure: aGVHD, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False